Please assess the completion status of the following clinical trial:

Trial Title: Heterologous Boost Immunization With an Aerosolised Ad5-nCoV After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Health subjects aged ≥18 years.~* Have received two-dose inactivated SARS-CoV-2 vaccine before 6 months or more.~* The subject can provide with informed consent and sign informed consent form (ICF).~* The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 6-month follow-up of the study.~Exclusion Criteria:~* Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.~* Be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination.~* Women with positive urine pregnancy test.~* Have acute febrile diseases and infectious diseases.~* Axillary temperature\>37.0℃.~* Have serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by medication (systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg when measured in the field).~* Have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease.~* Congenital or acquired angioedema / neuroedema.~* Have the history of urticaria 1 year before receiving the investigational vaccine.~* Have asplenia or functional asplenia.~* Patients with chronic obstructive pulmonary disease, pulmonary fibrosis and other pulmonary abnormalities.~* Have history of SARS-CoV-2 infection or COVID-19.~* Have symptoms of upper respiratory tract infection.~* Have traveled to medium or high risk areas or traveled abroad in the past 21 days, and epidemiologically contacted with SARS-CoV-2.~* Any medical, psychological, social, or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects in safety cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
- Group B (Type: EXPERIMENTAL): Subjects in immunogenicity cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
- Group C (Type: EXPERIMENTAL): Subjects in immunogenicity cohort will receive one homologous booster dose of ICV.

Based on this trial design, predict the completion outcome and termination type (if applicable).